Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma

Clinical trial NCT02211131 · COMPLETED

Trial details

NCT number: NCT02211131
Sponsor: Amgen
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma

Start date: 2015-02-03
Primary completion: 2019-04-30
Enrollment: 150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.